Eli Lilly is in advanced talks to acquire gene editing startup Verve Therapeutics for up to $1.3 billion, the Financial Times ...

Type 1 diabetes (T1D) is an autoimmune condition where the immune system destroys insulin-producing β-cells in the pancreas.